NASDAQ: TRIL
TSX: TRIL
TORONTO, Sept. 14, 2017 /PRNewswire/ - Trillium
Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage
immuno-oncology company developing innovative therapies for the
treatment of cancer, announced today that the company is scheduled
to present an update on the company's programs and progress at
several upcoming conferences.
Investor Conferences:
- Ladenburg Thalmann 2017 Healthcare Conference
Presenter: Dr. Robert Uger, Chief
Scientific Officer
Date and Time: September 26, 2017 at
9:00 a.m. EDT
Location: Hotel Sofitel, New York
City
- 2017 Cantor Fitzgerald Global Healthcare
Conference
Presenter: Dr. Niclas
Stiernholm, Chief Executive Officer
Date and Time: September 26, 2017 at
2:15 p.m. EDT
Location: Intercontinental Barclay Hotel, New York City
- Leerink Partners Roundtable Series: Rare Disease &
Immuno-Oncology
Presenters: Dr. Niclas Stiernholm, Chief Executive Officer and
Dr. Robert Uger, Chief Scientific
Officer
Date and Time: September 28, 2017 at
4:30 p.m. EDT
Location: Lotte New York Palace Hotel, New York City
A live audio webcast of the Leerink Partners presentation will
be available under the investor relations section of Trillium's
website at www.trilliumtherapeutics.com.
Scientific Conference:
- Cambridge Healthtech Institute's Inaugural "Targeting Tumor
Myeloid Cells"
Presenter: Dr. Lisa
Johnson, Research Scientist
Date and Time: September 28, 2017 at
9:35 a.m. EDT
Location: The Westin Copley Place, Boston
About Trillium Therapeutics
Trillium Therapeutics Inc. is a clinical stage immuno-oncology
company developing innovative therapies for the treatment of
cancer. The company's lead program, TTI-621, is a SIRPaFc fusion
protein that consists of the CD47-binding domain of human SIRPa
linked to the Fc region of a human immunoglobulin (IgG1). It is
designed to act as a soluble decoy receptor, preventing CD47 from
delivering its inhibitory ("do not eat") signal. Neutralization of
the inhibitory CD47 signal enables the activation of macrophage
anti-tumor effects by pro-phagocytic ("eat") signals. A Phase 1
clinical trial (NCT02663518) evaluating intravenous dosing of
SIRPaFc in patients with advanced cancer is ongoing, and a second
Phase 1 trial evaluating direct intratumoral injections is underway
in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an
IgG4 SIRPaFc protein, which is primarily being developed for
combination therapy. An IND filing is targeted for 2H/17. Trillium
also has a proprietary medicinal chemistry platform, using unique
fluorine chemistry, which permits the creation of new chemical
entities from validated drugs and drug candidates with improved
pharmacological properties. Stemming from this platform, the
company's most advanced preclinical program is an orally-available
epidermal growth factor receptor antagonist with increased uptake
and retention in the brain. In addition, a number of compounds
directed at undisclosed immuno-oncology targets are currently in
the discovery phase.
For more information visit:
www.trilliumtherapeutics.com
Neither TSX nor its Regulation Services Provider (as that term
is defined in the policies of the TSX) accepts responsibility for
the adequacy or accuracy of this release.
SOURCE Trillium Therapeutics Inc.